Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 12/20 | 0.67 |
| ▸ | TGM2 | P21980 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586111 | 0.82 | CES1 (0.52) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL734955 | 0.80 | CES1 (1.00) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL29253561 | 0.78 | CES1 (0.69) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL31103242 | 0.77 | CES1 (0.67) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL3391317 | 0.77 | CES1 (0.67) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL6177499 | 0.77 | CES1 (0.67) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL5738366 | 0.77 | CES1 (0.67) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL29700199 | 0.77 | CES1 (0.47) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL15353216 | 0.77 | CES1 (0.47) | CES1TGM2MAOAMAOBMEN1 | |
| SCHEMBL29700081 | 0.77 | CES1 (0.47) | CES1TGM2MAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | claimed |
| CN-111574426-A | Diamine monomer containing isoindigo structure and black polyimide synthesized from diamine monomer | 湘潭大学 | 2020-08-25 | — | — | CN | claimed |
| EP-4747235-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025017105-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025017103-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| CN-113912609-B | Preparation method of natural alkaloid tryptanthrin and derivatives thereof | 江苏大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-114685395-A | 2, 3-dihydrobenzo [ d ] isothiazole compound and application thereof | 浙江大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | disclosed |
| EP-3414247-B1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-5032597-A | Antitumor | DU PONT MERCK PHARMACEUTICAL (US) | 1991-07-16 | — | — | US | disclosed |
| EP-0133244-B1 | PHENYLQUINOLINECARBOXYLIC ACIDS AND DERIVATIVES AS ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-12-05 | — | — | EP | disclosed |
| US-4680299-A | ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0100906-B1 | TRI- AND TETRACYCLIC IMIDAZO(1,5-A)(1,4)BENZODIAZEPIN-1-CARBOXYLIC-ACID DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-05-13 | — | — | EP | disclosed |
| EP-0133244-A2 | Phenylquinolinecarboxylic acids and derivatives as antitumor agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
| US-4489003-A | ANTICONVULSANTS, TRANQUILLIZERS | HOFFMANN-LA ROCHE INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0100906-A2 | Tri- and tetracyclic imidazo(1,5-a)(1,4)benzodiazepin-1-carboxylic-acid derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-22 | — | — | EP | disclosed |
| US-4353827-A | ANTICONVULSIVE, ANXIOLYTIC | HOFFMANN-LA ROCHE INC. (US) | 1982-10-12 | — | — | US | disclosed |
| EP-0059391-A1 | Imidazodiazepines, process for their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | CES1 3568/4885TGM2 4320/4885MAOA 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.